GlobeNewswire: OncBioMune, L.L.C. Contains the last 10 of 106 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:17:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/07/15/1882725/0/en/OncBioMune-Announces-Compelling-Pre-clinical-Data-for-its-CD71-targeted-Chemotherapy-PGT-in-Models-of-Lung-Pancreatic-and-Ovarian-Cancers.html?f=22&fvtc=4&fvtv=38414OncBioMune Announces Compelling Pre-clinical Data for its CD71-targeted Chemotherapy, PGT, in Models of Lung, Pancreatic and Ovarian Cancers2019-07-15T13:42:45Z<![CDATA[BATON ROUGE, La., July 15, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and a CD71-targeted cancer therapy combining paclitaxel, gallium, and transferrin, or PGT, today announces the results of in vitro data for PGT in models of multi-drug resistant lung, pancreatic, and ovarian cancer.]]>https://www.globenewswire.com/news-release/2019/05/30/1859449/0/en/OncBioMune-Announces-Initial-In-Vitro-Proof-of-Concept-Data-for-PGT-in-a-Multi-Drug-Resistant-Ovarian-Cancer-Model.html?f=22&fvtc=4&fvtv=38414OncBioMune Announces Initial In Vitro Proof-of-Concept Data for PGT in a Multi-Drug Resistant Ovarian Cancer Model2019-05-30T13:08:19Z<![CDATA[BATON ROUGE, La., May 30, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and a CD71-targeted cancer therapy combining paclitaxel, gallium, and transferrin, otherwise known as PGT, today announces the results of initial in vitro data for PGT in a Multi-drug resistant ovarian cancer model.]]>https://www.globenewswire.com/news-release/2019/05/01/1813596/0/en/OncBioMune-Announces-Agreement-with-CATO-BioVentures-as-a-Strategic-Investor-in-Support-of-CD71-Targeted-Therapy-for-Refractory-Cancers.html?f=22&fvtc=4&fvtv=38414OncBioMune Announces Agreement with CATO BioVentures as a Strategic Investor in Support of CD71-Targeted Therapy for Refractory Cancers2019-05-01T13:28:59Z<![CDATA[BATON ROUGE, La., May 01, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapy, is pleased to announce that it has received a letter of interest from CATO BioVentures, the venture capital affiliate of Cato Holding, a privately held family fund.]]>https://www.globenewswire.com/news-release/2019/03/19/1757023/0/en/Phase-2-Trial-of-OncBioMune-s-Immunotherapy-Cancer-Vaccine-ProscaVax-for-Prostate-Cancer-Patients-in-Active-Surveillance-Now-Open-for-Enrollment.html?f=22&fvtc=4&fvtv=38414Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment2019-03-19T12:30:00Z<![CDATA[BATON ROUGE, La., March 19, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic prostate cancer vaccine immunotherapy and CD71-targeted cancer therapy, today announces that the Phase 2, randomized study of ProscaVax in treatment-naïve patients with clinically localized prostate cancer vs active surveillance is now open for enrollment.]]>https://www.globenewswire.com/news-release/2019/02/28/1744312/0/en/OncBioMune-Announces-Consulting-Agreement-with-CATO-Research-LLC-for-Developing-PGT-a-Protein-Drug-Complex-Targeting-CD71-for-Refractory-Cancers.html?f=22&fvtc=4&fvtv=38414OncBioMune Announces Consulting Agreement with CATO Research LLC for Developing PGT, a Protein Drug Complex Targeting CD71 for Refractory Cancers2019-02-28T13:29:00Z<![CDATA[BATON ROUGE, La., Feb. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapy, is pleased to announce that it has entered into a consulting agreement with CATO Research, LLC, a global provider of regulatory and clinical research services, effective immediately.]]>https://www.globenewswire.com/news-release/2019/01/28/1706138/0/en/Dr-Mitesh-Borad-Joins-OncBioMune-Scientific-Advisory-Board.html?f=22&fvtc=4&fvtv=38414Dr. Mitesh Borad Joins OncBioMune Scientific Advisory Board2019-01-28T13:54:36Z<![CDATA[BATON ROUGE, La., Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to announce the appointment of Mitesh J. Borad, M.D. to the Company’s Scientific Advisory Board, effective immediately.]]>https://www.globenewswire.com/news-release/2019/01/09/1682746/0/en/OncBioMune-Announces-Former-Puma-Biotechnology-Executive-and-Genentech-Veteran-Brian-Barnett-M-D-as-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=38414OncBioMune Announces Former Puma Biotechnology Executive and Genentech Veteran Brian Barnett, M.D., as Chief Executive Officer2019-01-09T13:28:00Z<![CDATA[BATON ROUGE, La., Jan. 09, 2019 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today announces that its Board of Directors has appointed Brian Barnett, M.D., as Chief Executive Officer.]]>https://www.globenewswire.com/news-release/2018/12/07/1663797/0/en/Site-Visit-Planned-for-December-19-2018-to-Initiate-Phase-2-Trial-of-ProscaVax-for-Early-Stage-Prostate-Cancer.html?f=22&fvtc=4&fvtv=38414Site Visit Planned for December 19, 2018 to Initiate Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer2018-12-07T14:00:00Z<![CDATA[BATON ROUGE, La., Dec. 07, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to provide an update on the Phase 2 clinical trial of ProscaVax being hosted at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital of Harvard University. In the clinical trial, ProscaVax, the Company’s lead immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), is being evaluated for safety and efficacy in patients with low-risk localized prostate cancer compared to patients in “Active Surveillance.”]]>https://www.globenewswire.com/news-release/2018/11/08/1648117/0/en/OncBioMune-Phase-2-Clinical-Trial-to-Begin-Enrollment-Company-Announces-Other-Developments-and-Corporate-Milestones.html?f=22&fvtc=4&fvtv=38414OncBioMune Phase 2 Clinical Trial to Begin Enrollment; Company Announces Other Developments and Corporate Milestones2018-11-08T14:08:00Z<![CDATA[BATON ROUGE, La., Nov. 08, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, today provides an update on its upcoming Phase 2 clinical trials of ProscaVax for prostate cancer and other corporate developments.]]>https://www.globenewswire.com/news-release/2018/10/31/1640285/0/en/OncBioMune-CEO-Dr-Jonathan-Head-Speaking-at-2018-Global-Summit-on-Genitourinary-Malignancies.html?f=22&fvtc=4&fvtv=38414OncBioMune CEO Dr. Jonathan Head Speaking at 2018 Global Summit on Genitourinary Malignancies2018-10-31T13:00:00Z<![CDATA[BATON ROUGE, La., Oct. 31, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary therapeutic cancer vaccine immunotherapy and targeted cancer therapies, is pleased to inform shareholders that the Company’s CEO, Dr. Jonathan Head, has been asked to present alongside other well renowned faculty speakers at Oncology Meeting Innovations’ 2018 Global Summit on Genitourinary Malignancies. This year’s conference is being held November 1-4, 2018 at Fairmont Banff Springs hotel in Banff, Alberta, Canada.]]>